Given that ALL patients have a wild-type p53 with often elevated levels of FLT4/VEGFC, and resistance to DNA damage-induced apoptosis, we investigated whether the modulation of MDM2/MDMX complex sits at the interface of FLT4 and p53 activity. This evidence concerns the gene VEGFC and acute lymphoblastic leukemia.